Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections

Am Rev Respir Dis. 1987 Aug;136(2):329-33. doi: 10.1164/ajrccm/136.2.329.

Abstract

Rifabutin (ansamycin LM 427) when given alone in doses of 5, 10, or 20 mg/kg showed limited in vivo activity against acute or chronic Mycobacterium intracellulare infections studied in beige C57B1/6, or S/W mice. Prophylactic studies in S/W mice in which chemotherapy was given for 3 wk prior to challenge showed slight improvement. Combination chemotherapy consisting of rifabutin (10 mg/kg) and clofazimine (20 mg/kg) achieved complete sterilization of M. intracellulare infections in spleen and lung when initiated immediately after challenge. Inclusion of ethambutol did not offer additional benefit. If chemotherapy is initiated 3 wk after challenge (established infections), the activity of this double drug combination is less effective.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Chronic Disease
  • Clofazimine / therapeutic use*
  • Drug Therapy, Combination
  • Ethambutol / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mycobacterium avium
  • Rifabutin
  • Rifamycins / therapeutic use*
  • Tuberculosis / drug therapy*

Substances

  • Rifamycins
  • Rifabutin
  • Ethambutol
  • Clofazimine